Cargando…

Combined treatment with valsartan and fluvastatin to delay disease progression in nonpermanent atrial fibrillation with hypertension: A clinical trial

BACKGROUND: Atrial fibrillation (AF) is a complex cardiac arrhythmia in clinical practice with increasing incidence. However, the effects of statins on patients with AF are not quite clear. HYPOTHESIS: To investigate the protective effect of calcium channel blocker (CCB) and valsartan combined fluva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Zhiqiang, Yang, Yu, Wang, Jianwei, Dong, Zhaojie, Niu, Xiaowei, Liu, Enzhao, Liu, Tong, Li, Lifeng, Liang, Yingzi, Li, Guangping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Periodicals, Inc. 2020
Materias:	Clinical Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724225/ https://www.ncbi.nlm.nih.gov/pubmed/33103770 http://dx.doi.org/10.1002/clc.23487

Ejemplares similares

Change in Atrial Fibrillation Burden over Time in Patients with Nonpermanent Atrial Fibrillation
por: Krisai, Philipp, et al.
Publicado: (2020)

Fluvastatin therapy could not decrease progression of paroxysmal atrial fibrillation in non-valvular disease patients
por: Tan, Qiang, et al.
Publicado: (2017)

Cilostazol ameliorates atrial ionic remodeling in long-term rapid atrial pacing dogs
por: Zhao, Zhiqiang, et al.
Publicado: (2016)

Upstream therapeutic strategies of Valsartan and Fluvastatin on Hypertensive patients with non-permanent Atrial Fibrillation (VF-HT-AF): study protocol for a randomized controlled trial
por: Qi, Wen-Wei, et al.
Publicado: (2015)

Clinical Characteristics, Management, and Control of Permanent vs. Nonpermanent Atrial Fibrillation: Insights from the RealiseAF Survey
por: Murin, Jan, et al.
Publicado: (2014)

Complications of Nonpermanent Facial Fillers: A Systematic Review
por: Oranges, Carlo M., et al.
Publicado: (2021)

Biomarkers for Predicting Left Atrial or Left Atrial Appendage Thrombus in Anticoagulated Patients with Nonvalvular Atrial Fibrillation
por: Zhou, Xue, et al.
Publicado: (2020)

Serum Beta-2 Microglobulin: A Possible Biomarker for Atrial Fibrillation
por: Zhang, Bangying, et al.
Publicado: (2021)

Sacubitril/Valsartan Improves Left Atrial and Left Atrial Appendage Function in Patients With Atrial Fibrillation and in Pressure Overload-Induced Mice
por: Suo, Ya, et al.
Publicado: (2019)

Sacubitril/valsartan attenuates atrial structural remodelling in atrial fibrillation patients
por: Yang, Liu, et al.
Publicado: (2022)

The potential role of atrial natriuretic peptide in the effects of Angiotensin-(1–7) in a chronic atrial tachycardia canine model
por: Zhao, Jun, et al.
Publicado: (2016)

The Therapeutic Potential of MicroRNAs in Atrial Fibrillation
por: Xu, Xiaona, et al.
Publicado: (2020)

Modulation of Ion Channels in the Superior Cervical Ganglion Neurons by Myocardial Ischemia and Fluvastatin Treatment
por: Cheng, Lijun, et al.
Publicado: (2018)

Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre–Heart Failure With Preserved Ejection Fraction: The PARABLE Randomized Clinical Trial
por: Ledwidge, Mark, et al.
Publicado: (2023)

Upstream Therapy for Atrial Fibrillation Prevention: The Role of Sacubitril/Valsartan
por: De Vecchis, Renato, et al.
Publicado: (2020)

A Low-Dose Combination of Fluvastatin and Valsartan: A New “Drug” and a New Approach for Decreasing the Arterial Age
por: Janić, Miodrag, et al.
Publicado: (2015)

Evaluation of the association between stroke/transient ischemic attack and atrial electromechanical delay in patients with paroxysmal atrial fibrillation
por: Bayar, Nermin, et al.
Publicado: (2016)

A Combination of Low Doses of Fluvastatin and Valsartan Decreases Arterial Stiffness in Patients After Myocardial Infarction: A Pilot Study
por: Hanžel, Jurij, et al.
Publicado: (2015)

Expression of Longevity Genes Induced by a Low-Dose Fluvastatin and Valsartan Combination with the Potential to Prevent/Treat “Aging-Related Disorders”
por: Janić, Miodrag, et al.
Publicado: (2019)

Predictive value of HMGB1 for atrial fibrillation recurrence after cryoballoon ablation in paroxysmal atrial fibrillation patients
por: Li, Xinxin, et al.
Publicado: (2022)

Enantiospecific Pharmacogenomics of Fluvastatin
por: Hirvensalo, Päivi, et al.
Publicado: (2019)

Efficacy of Wenxin Keli Plus Amiodarone versus Amiodarone Monotherapy in Treating Recent-Onset Atrial Fibrillation
por: Zhang, Nixiao, et al.
Publicado: (2018)

Effect of Sacubitril-Valsartan on Restoration and Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation
por: Chen, Qingsong, et al.
Publicado: (2022)

Connexin 43 is involved in the sympathetic atrial fibrillation in canine and canine atrial myocytes
por: Shu, Chenglin, et al.
Publicado: (2017)

Effect of valsartan on atrial fibrillation recurrence following pulmonary vein isolation in patients
por: CUI, YINGKAI, et al.
Publicado: (2015)

The Difference in Pharmacokinetics and Pharmacodynamics between Extended-Release Fluvastatin and Immediate-Release Fluvastatin in Healthy Chinese Subjects
por: Xu, H. R., et al.
Publicado: (2012)

Improving Arterial Wall Characteristics in Patients After Myocardial Infarction with a Very Low Dose of Fluvastatin and Valsartan: A Proof-of-Concept Study
por: Veselič, Martina Turk, et al.
Publicado: (2018)

Associations of anemia with death and major bleeding in patients with atrial fibrillation: A report from the Chinese Atrial Fibrillation Registry Study
por: Zhang, Zhuxin, et al.
Publicado: (2021)

Safety and efficacy of ablation for atrial fibrillation in combination with left atrial appendage occlusion in octogenarians
por: Zhang, Peng‐Pai, et al.
Publicado: (2023)

Age at Diagnosis of Atrial Fibrillation and Incident Dementia
por: Zhang, Wenya, et al.
Publicado: (2023)

NT Pro‐BNP can be used as a risk predictor of clinical atrial fibrillation with or without left atrial enlargement
por: Zhao, Xiao, et al.
Publicado: (2021)

Left atrial appendage size is a marker of atrial fibrillation recurrence after radiofrequency catheter ablation in patients with persistent atrial fibrillation
por: Simon, Judit, et al.
Publicado: (2021)

Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma
por: Cheng, Yang, et al.
Publicado: (2017)

Thiazolidinedione use and atrial fibrillation in diabetic patients: a meta-analysis
por: Zhang, Zhiwei, et al.
Publicado: (2017)

Effects of Fluvastatin on the Pharmacokinetics of Repaglinide: Possible Role of CYP3A4 and P-glycoprotein Inhibition by Fluvastatin
por: Lee, Chong-Ki, et al.
Publicado: (2013)

The immediate trends in atrial electrical remodeling for paroxysmal atrial fibrillation across different modes of catheter ablation
por: Hou, Qian, et al.
Publicado: (2021)

Left atrial dyssynchrony time measured by tissue Doppler imaging to predict atrial fibrillation recurrences after pulmonary vein isolation
por: Salah, Ahmed, et al.
Publicado: (2015)

Atrial fibrillation and its arrhythmogenesis associated with insulin resistance
por: Chan, Yi-Hsin, et al.
Publicado: (2019)

Catheter Ablation With Morphologic Repetitiveness Mapping for Persistent Atrial Fibrillation
por: Lin, Chin-Yu, et al.
Publicado: (2023)

N‐terminal pro‐B‐type natriuretic peptide and D‐dimer combined with left atrial diameter to predict the risk of ischemic stroke in nonvalvular atrial fibrillation
por: Shen, Zican, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o1q2r0nj144phcqjdvfa6kju4o